Analyst Price Target is $16.75
▲ +458.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Reviva Pharmaceuticals in the last 3 months. The average price target is $16.75, with a high forecast of $20.00 and a low forecast of $12.00. The average price target represents a 458.33% upside from the last price of $3.00.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Reviva Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.
Read More
